Bachem Holding AG operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bachem Holding AG with three other
miscellaneous service companies in Europe:
sales of 2.48 billion Swedish Kronor [US$257.57 million]
of which 58%
Pharma Mar SA
(162.59 million Euro [US$181.06 million]
of which 67%
was Biotech Sector), and
based in Belgium
(317.85 million Euro [US$353.95 million]
of which 88%
Bachem Holding AG reported sales of 282.50 million Swiss Francs (US$290.34 million)
December of 2018.
increase of 8.0%
versus 2017, when the company's sales were 261.61 million Swiss Francs.
Sales at Bachem Holding AG have increased during each of the previous five years
(and since 2013, sales have increased a total of 66%).
Sales of Active Pharmaceutical Ingredients saw an increase
10.0% in 2018, from
229.74 million Swiss Francs to 252.67 million Swiss Francs.
Not all segments of Bachem Holding AG experienced an increase in sales in 2018:
sales of Research Ingredients fell 6.4% to 29.83 million Swiss Francs.